Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2016

Open Access 01-12-2016 | Research Article

LIN7A is a major determinant of cell-polarity defects in breast carcinomas

Authors: Nadège Gruel, Laetitia Fuhrmann, Catalina Lodillinsky, Vanessa Benhamo, Odette Mariani, Aurélie Cédenot, Laurent Arnould, Gaëtan Macgrogan, Xavier Sastre-Garau, Philippe Chavrier, Olivier Delattre, Anne Vincent-Salomon

Published in: Breast Cancer Research | Issue 1/2016

Login to get access

Abstract

Background

Polarity defects are a hallmark of most carcinomas. Cells from invasive micropapillary carcinomas (IMPCs) of the breast are characterized by a striking cell polarity inversion and represent an interesting model for the analysis of polarity abnormalities.

Methods

In-depth investigation of polarity proteins in 24 IMPCs and a gene expression profiling, comparing IMPC (n = 73) with invasive carcinomas of no special type (ICNST) (n = 51) have been performed.

Results

IMPCs showed a profound disorganization of the investigated polarity proteins and revealed major abnormalities in their subcellular localization. Gene expression profiling experiments highlighted a number of deregulated genes in the IMPCs that have a role in apico-basal polarity, adhesion and migration. LIN7A, a Crumbs-complex polarity gene, was one of the most differentially over-expressed genes in the IMPCs. Upon LIN7A over-expression, we observed hyperproliferation, invasion and a complete absence of lumen formation, revealing strong polarity defects.

Conclusion

This study therefore shows that LIN7A has a crucial role in the polarity abnormalities associated with breast carcinogenesis.
Appendix
Available only for authorised users
Literature
1.
Luna-More S, Gonzalez B, Acedo C, Rodrigo I, Luna C. Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol Res Pract. 1994;190:668–74.CrossRefPubMed
2.
Gruel N, Cedenot A, Richardson M, Fréneaux P, Bhalshankar J, Dubois T, et al. Inverted apical CD24 and weak EZH2 expressions are phenotypic characteristics of pure invasive micropapillary carcinoma of the breast. Open J Pathol. 2013;3:85–95.CrossRef
3.
Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, et al. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer. 2014;111:619–22.CrossRefPubMedPubMedCentral
4.
Gruel N, Benhamo V, Bhalshankar J, Popova T, Freneaux P, Arnould L, et al. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. Breast Cancer Res. 2014;16:R46.CrossRefPubMedPubMedCentral
5.
Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, et al. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell. 2008;135:865–78.CrossRefPubMedPubMedCentral
6.
McCaffrey LM, Montalbano J, Mihai C, Macara IG. Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell. 2012;22:601–14.CrossRefPubMedPubMedCentral
7.
Xue B, Krishnamurthy K, Allred DC, Muthuswamy SK. Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol. 2013;15:189–200.CrossRefPubMed
8.
Huang L, Muthuswamy SK. Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. Curr Opin Genet Dev. 2010;20:41–50.CrossRefPubMedPubMedCentral
9.
Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003;30:256–68.CrossRefPubMed
10.
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555–77.CrossRefPubMedPubMedCentral
11.
Ellenbroek SI, Iden S, Collard JG. Cell polarity proteins and cancer. Semin Cancer Biol. 2012;22:208–15.CrossRefPubMed
12.
13.
Bulgakova NA, Knust E. The Crumbs complex: from epithelial-cell polarity to retinal degeneration. J Cell Sci. 2009;122:2587–96.CrossRefPubMed
14.
Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP, et al. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol. 2006;8:1235–45.CrossRefPubMed
15.
Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, et al. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res. 2014;74:3180–94.CrossRefPubMedPubMedCentral
16.
Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol. 2008;216:399–407.CrossRefPubMed
17.
Nassar H, Wallis T, Andea A, Dey J, Adsay V, Visscher D. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol. 2001;14:836–41.CrossRefPubMed
18.
Zhang K, Zhao H, Ji Z, Zhang C, Zhou P, Wang L, et al. Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition. Oncogene. 2015. doi:10.​1038/​onc.​2015.​184.
19.
Jaulin-Bastard F, Arsanto JP, Le Bivic A, Navarro C, Vely F, Saito H, et al. Interaction between Erbin and a Catenin-related protein in epithelial cells. J Biol Chem. 2002;277:2869–75.CrossRefPubMed
20.
Kaech SM, Whitfield CW, Kim SK. The LIN-2/LIN-7/LIN-10 complex mediates basolateral membrane localization of the C. elegans EGF receptor LET-23 in vulval epithelial cells. Cell. 1998;94:761–71.CrossRefPubMedPubMedCentral
21.
Abu-Thuraia A, Gauthier R, Chidiac R, Fukui Y, Screaton RA, Gratton JP, et al. Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion. Mol Cell Biol. 2015;35:76–87.CrossRefPubMed
Metadata
Title
LIN7A is a major determinant of cell-polarity defects in breast carcinomas
Authors
Nadège Gruel
Laetitia Fuhrmann
Catalina Lodillinsky
Vanessa Benhamo
Odette Mariani
Aurélie Cédenot
Laurent Arnould
Gaëtan Macgrogan
Xavier Sastre-Garau
Philippe Chavrier
Olivier Delattre
Anne Vincent-Salomon
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2016
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-016-0680-x

Other articles of this Issue 1/2016

Breast Cancer Research 1/2016 Go to the issue

Letter

SEARCHBreast: a new online resource to make surplus material from in vivo models of breast cancer visible and accessible to researchers

Research article

Paternal programming of breast cancer risk in daughters in a rat model: opposing effects of animal- and plant-based high-fat diets

Review

The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance

Research article

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

Research article

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells

Research article

Case-control study of mammographic density and breast cancer risk using processed digital mammograms
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits